Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
JENNIFER COOK	Director	2026-07-09	149K shares	$13.16M
ANDREA ELLIS	Director	2026-07-09	17K shares	$1.44M
Cook Jennifer E.	Director	2026-06-24	37K shares	$2.60M
Scott Randal W.	Director	2026-06-24	2K shares	$151K
Cook Jennifer E.	Director	2026-06-23	2K shares	$151K
Valantine Hannah	Director	2026-06-23	2K shares	$151K
Valantine Hannah	Director	2026-06-22	3K shares	$191K
Cook Jennifer E.	Director	2026-06-15	90K shares	$6.01M

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

Active 5%+ Holders

Data as of 2026-07-10

Reporting Person	Type	Filing Date	Shares	% of Class
VIKING GLOBAL INVESTORS LP	13D/A	2026-07-10	9.79M	5.0%

View all Schedule 13D/13G filings

Material Events (8-K)

Filings (14d)

Data as of 2026-07-02

2026-07-02

BridgeBio Pharma raised $933.9 million by issuing 933,900 shares of Series A convertible preferred stock at $1,000 each to Sixth Street and an affiliate of KKR. The preferred stock carries a 7% annual dividend, is convertible into common stock at $137.79 per share initially, and includes provisions for forced conversion or redemption by the company after certain periods.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding BRIDGEBIO PHARMA INC (BBIO)?

Major stakeholders currently include BlackRock, Inc. ($1.1B), Kohlberg Kravis Roberts & Co. L.P. ($984.8M), Janus Henderson Group PLC ($978.6M). Based on the latest 13F filings, there are a total of 459 tracked investment funds and institutions maintaining positions in BBIO.

What is the overall institutional sentiment toward BBIO recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $92.1M, driven by 257 managers accumulating shares while 201 reduced their exposure.

Which institutions have been selling or reducing their BBIO positions?

In the latest period, 140 funds trimmed their holdings, and 61 managers completely exited their positions. The aggregate reported sell value was $6.8B.

Are there any notable investors adding BBIO to their portfolios?

Yes, buying activity remains notable. 77 institutions opened new positions in {ticker}, and 180 existing holders added to their shares. The total reported buy value for the quarter amounted to $7.1B.